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ABSTRACT
The diagnosis of a potentially lethal cardiovascular 
disease in a young athlete presents a complex dilemma 
regarding athlete safety, patient autonomy, team or 
institutional risk tolerance and medical decision- making. 
Consensus cardiology recommendations previously 
supported the ’blanket’ disqualification of athletes with 
hypertrophic cardiomyopathy (HCM) from competitive 
sport. More recently, epidemiological studies examining 
the relative contribution of HCM as a cause of sudden 
cardiac death (SCD) in young athletes and reports from 
small cohorts of older athletes with HCM that continue 
to exercise have fueled debate whether it is safe to play 
with HCM. Shared decision- making is endorsed within 
the sports cardiology community in which athletes can 
make an informed decision about treatment options 
and potentially elect to continue competitive sports 
participation. This review critically examines the available 
evidence relevant to sports eligibility decisions in young 
athletes diagnosed with HCM. Histopathologically, 
HCM presents an unstable myocardial substrate that 
is vulnerable to ventricular tachyarrhythmias during 
exercise. Studies support that young age and intense 
competitive sports are risk factors for SCD in patients 
with HCM. We provide an estimate of annual mortality 
based on our understanding of disease prevalence and 
the incidence of HCM- related SCD in different athlete 
populations. Adolescent and young adult male athletes 
and athletes participating in a higher risk sport such 
as basketball, soccer and American football exhibit a 
greater risk. This review explores the potential harms 
and benefits of sports disqualification in athletes with 
HCM and details the challenges and limitations of shared 
decision- making when all parties may not agree.
‘Medicine is a science of uncertainty and an art of 
probability’.—William Osler (1849–1919)
INTRODUCTION
Sudden cardiac arrest (SCA) is the leading cause of 
sudden death in young competitive athletes during 
sports and exercise.1–3 The aetiology of SCA in 
young athletes (<30 years of age) includes a diverse 
group of genetic and congenital cardiac diseases 
such as cardiomyopathies, ion channel disorders 
and anomalous coronary arteries. Early detection of 
conditions at elevated risk of SCA through cardio-
vascular screening allows the potential for risk 
reduction by disease- specific management and indi-
vidualised activity restrictions.4 In 2005, both the 
American Heart Association (AHA) and European 
Society of Cardiology (ESC) advised the routine 
disqualification of athletes from competitive sport 
following the diagnosis of a potentially sinister 
cardiac disorder capable of causing sudden cardiac 
death (SCD).5 6 However, new guidelines by the 
AHA/American College of Cardiology (2015) and 
the ESC/European Association of Preventive Cardi-
ology (2019) no longer support a simple binary 
‘yes/no’ approach to sports eligibility decisions.7 8
Pelliccia et al recently reported results in adult 
patients with hypertrophic cardiomyopathy (HCM) 
and the risk of major adverse cardiovascular events 
with and without continued sports participation.9 
In 88 adult athletes (median age 31 years) with a 
predominantly low- risk HCM phenotype followed 
for a 7- year period, the study found no difference 
in the risk of SCA in patients choosing to continue 
competitive sports versus those who selected out 
of intensive exercise.9 While the study lacks power 
to draw definitive conclusions, the results provide 
important data to inform activity recommendations 
in middle- aged adult athletes with HCM. However, 
the authors appropriately caution that these results 
should not be applied to adolescent and younger 
adult athletes or those with a more severe HCM 
phenotype where the risk of SCD with intensive 
exercise may be higher.
How should these results impact a rapidly 
evolving paradigm for sports eligibility decisions in 
athletes identified with conditions at risk for SCA/
SCD? This review addresses the principles and 
limitations of shared decision- making in the context 
of a potentially lethal cardiovascular disorder, with 
specific focus on the risks and current controversy 
of allowing competitive athletes with HCM to 
return to play. A critical analysis of HCM- related 
SCD is presented to guide evidence- informed sports 
eligibility decisions. While not the primary intent of 
this review, the information presented may be appli-
cable to young persons diagnosed with HCM who 
wish to engage in recreational sports and exercise.
SHARED DECISION-MAKING IN SPORTS 
CARDIOLOGY
Shared decision- making is a collaborative process 
between the patient, other stakeholders (eg, 
parents) and the physician that combines the princi-
ples of informed consent and patient autonomy.10 11 
A shared decision- making approach considers the 
values and preferences of the patient and is espe-
cially important when more than one management 
option is reasonable. Within sports cardiology eligi-
bility decisions, all stakeholders in the outcome 
are ideally involved in the decision process with 
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consent from the patient (or parents of children), including 
family members, athletic trainers, physiotherapists, team physi-
cians, cardiologists, coaches and team, school or club officials. 
A thoughtful discussion of the potential harms and benefits of 
different treatment options, including continued competitive 
sports participation, should be explored using the best available 
evidence. Ideally, the final decision should be acceptable to all 
parties.
A paradigm shift has evolved regarding a return to sport for 
competitive athletes diagnosed with cardiovascular disease.10 12 
Disorders that once led to universal sports disqualification are 
now considered for return to play on a case- by- case basis. Shared 
decision- making in sports cardiology was first highlighted in 
young individuals with long QT syndrome (LQTS).13 Two 
observational studies both reported that young athletes with 
genotype- positive LQTS who underwent appropriate coun-
selling, optimal medical management and remained treatment 
compliant could return to sport with a low rate of SCA and no 
increase in mortality.13 14
However, risk mitigation for other cardiovascular diseases that 
afflict young athletes may not be possible. For instance, compel-
ling data indicate that intense exercise increases the risk of 
ventricular arrhythmias and disease progression in patients with 
arrhythmogenic cardiomyopathy.15–18 Indeed, recommendations 
against competitive sports for patients diagnosed with arrhyth-
mogenic cardiomyopathy remain universally supported among 
sports cardiology experts. Thus, patient autonomy regarding 
sports participation is not absolute, and shared decision- making 
should not be oversimplified as a process where the athlete 
simply makes the decision.
HCM-RELATED SCD IN THE YOUNG
How should we approach shared decision- making for athletes 
diagnosed with HCM? Specifically, is there evidence that 
vigorous exercise or competitive sport increases SCD risk in 
young athletes with HCM and would exercise restrictions lower 
their risk? Conversely, is there a subgroup of athletes with HCM 
who may be able to safely participate in intensive exercise?
Although SCD in sport is relatively uncommon, HCM is 
frequently diagnosed at autopsy in young athletes, especially 
in countries without systematic inclusion of a 12- lead ECG in 
the preparticipation screening programme. Such circumstantial 
evidence supports that HCM is associated with SCD in young 
competitive athletes. However, the actual proportion of cases 
attributable to HCM is variable and may be dependent on the 
quality of the postmortem examination to differentiate HCM 
from left ventricular hypertrophy (LVH) commonly found in 
athletes. In a series of 1306 athletes with SCD in the USA, 842 
had an autopsy- confirmed cardiovascular diagnosis. HCM was 
the leading identified structural disorder representing 36% of 
confirmed diagnoses and 23% of all cardiovascular cases.3 An 
analysis of SCD in college athletes from the USA as well as a 
prospective study of elite adolescent soccer players from the 
UK both found that HCM represented about one- third of SCD 
cases (33%–37%).19 20 While other studies have reported a lower 
proportion of SCD cases due to HCM (6%–16%), HCM remains 
an important cause of SCD in young athletes.1 2 21 22
Early studies also demonstrated that SCD is more common 
in younger patients with HCM. A 1982 report examined 
autopsy and patient records in 78 patients with HCM from 
the National Heart, Lung, and Blood Institute and found that 
71% of SCD cases occurred before age 30% and 63% of these 
occurred during exertion.23 A 2000 report of 86 patients with 
HCM- related deaths also found that SCD was more common in 
younger patients (age 5–25 years) compared with HCM- related 
stroke and heart failure as the cause of death in older patients.24 
A Portuguese registry of 1042 patients with HCM (mean age 
53±16 years) also found that heart failure was the most common 
cause of death in older patients.25
ANNUAL SCD MORTALITY RATE IN PATIENTS WITH HCM
The risk of SCD in patients with HCM is impacted by several 
factors including age, symptoms, family history, disease 
morphology and electrodiagnostics. Early studies reported an 
annual mortality rate of approximately 4% in children with 
HCM.26 27 In a 1976 study of 35 children with HCM (age <15 
years) followed for 7.4 years, one- third of patients died suddenly 
(4% mortality per year).26 Similarly, a 1984 study examined 37 
children (ages 1–14 years at diagnosis) followed for 9 years and 
reported an annual mortality rate of 4.3%.27 More recently, a 
2011 study from the National Institute of Health followed 131 
younger patients (≤20 years of age) for a median of 6.4 years.28 
The annual rate of sudden death or life- threatening arrhythmic 
events was 2%, with a mean age of 20.1 years at the time of 
the arrhythmic event and a higher risk if septal thickness was 
≥20 mm.28
Conventional risk markers for patients with HCM include 
a prior cardiac arrest, family history of HCM- related sudden 
death, unexplained recent syncope, multiple episodes of non- 
sustained ventricular tachycardia (VT), massive LVH (wall thick-
ness ≥30 mm), left ventricular apical aneurysm or an ejection 
fraction <50%0.29 Other potential risk mediators include exten-
sive late gadolinium enhancement on cardiac MRI, a hypoten-
sive response to exercise, or marked left ventricular outflow 
tract obstruction at rest. Patients with one or more major risk 
markers have a primary indication for an implantable cardio-
verter defibrillator (ICD) and a predicted event rate for VT or 
ventricular fibrillation (VF) of 4% per year.29
Risk stratification and selective use of ICDs have greatly 
improved HCM- related mortality.30–33 In 474 younger patients 
with HCM between 7 and 29 years (mean age 20) with an 
average follow- up of 7.1 years, 5- year and 10- year survival 
with application of existing cardiovascular treatment strategies 
was 97% and 94%, respectively.30 Sixty- three patients experi-
enced sudden death, resuscitated cardiac arrest or appropriate 
ICD intervention—an annual risk of 1.8% per year including 
non- fatal HCM events.30 Predictors of HCM mortality and non- 
fatal aborted events after multivariate analysis included younger 
age at diagnosis, increased left atrial dimension and greater left 
ventricular thickness.30
Survival has also improved in older adults with HCM through 
an enhanced American College of Cardiology/AHA risk stratifi-
cation model combined with contemporary management strate-
gies. In a cohort of 2094 patients with HCM (mean age 51), 527 
received primary prevention ICDs. During a mean follow- up of 
4.7 years, 82 (15.6%) patients experienced device terminated 
VT/VF and no patient with an ICD died from SCD.33 In the 
1567 patients without an ICD, 12 (0.8%) had SCA/SCD, of 
which 7 patients had high- risk indicators but declined an ICD.33 
Overall, the annual mortality rate was only 0.1%, supporting 
that a modern risk stratification and prevention model may 
avert most SCD in a general population of predominantly older 
patients with HCM.33
Limited data are available regarding the use of ICDs in 
competitive athletes with HCM. The ICD sports safety registry 
studied 328 patients (mean age 33 years) for ICD events over a 
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median follow- up of 31 months and documented no deaths or 
resuscitated cardiac arrests.34 However, within this cohort, only 
60 patients were considered competitive athletes and only 13 
had HCM.34 This study provides initial evidence that continued 
sports participation for patients with HCM and an ICD may be 
safe, although the small sample size does not allow for definitive 
conclusions.
RACE, SPORT AND HCM-RELATED SCD
There is a potential association of race and HCM- related SCD 
in young athletes.35 In an autopsy- confirmed series of 842 cases 
of SCD in athletes (aged 19±6 years) in the USA, the cardiovas-
cular death rate was fivefold higher among African Americans 
and other minorities than among whites (1:12 778 vs 1:60 746 
athlete- years; p<0.001), and HCM accounted for 42% of cases 
in African Americans and other minorities versus 31% of cases 
in white athletes (p<0.001).3 Similarly, in a prospective study of 
SCA/SCD in US competitive athletes including 19 HCM- related 
cases, HCM represented 30.3% of confirmed diagnoses in male 
African American athletes compared with only 10.0% of male 
white athletes (p=0.0186).2 In contrast, a study of 425 older 
patients with HCM (163 black and 262 white; mean age 52.5 
years) from the UK found no difference in the composite primary 
outcome of cardiovascular death, cardiac arrest or appropriate 
device therapy over a mean follow- up of 4.3 years (Kaplan- 
Meier survival analysis, p logrank=0.095).36 These divergent 
findings regarding the relationship of race and SCD may reflect 
a difference in risk between young athletes engaging in stren-
uous exercise compared with a more benign clinical course in 
older patients with HCM. In addition, the higher prevalence of 
HCM as a cause of SCD among young black athletes may be 
in part ascribed to a greater increase in physiological LVH in 
Afro- Caribbean athletes that can be misinterpreted as HCM at 
postmortem examination.37 38
HCM also accounts for a higher proportion of cases in male 
basketball (23.3%) and American football (25%) athletes than 
in other sports.2 Studies examining US college athletes also have 
documented higher rates of cardiomyopathy as a cause of SCD 
in male basketball and American football athletes.1 19 Similarly, 
in a prospective study of adolescent soccer players (95% male), 
HCM accounted for 3 of 8 (37%) SCD cases observed over a 
mean follow- up period of 10.6 years.20 Thus, HCM may repre-
sent a disproportionate number of SCA/SCD events in higher 
risk athlete groups—younger black athletes, male basketball, 
male soccer and American football—underscoring the need for 
additional caution when considering a return to competitive 
sports within these risk groups.
CAN WE QUANTIFY THE RISK OF SCD IN ATHLETES WITH 
HCM?
SCD from HCM is inherently unpredictable. We have little 
understanding of the inciting event that suddenly leads to a lethal 
ventricular tachyarrhythmia in athletes who may have harboured 
their disease for years. Furthermore, the stresses of the athletic 
arena are not fully reflected in laboratory testing, highlighting 
the need for large longitudinal studies. Risk calculators have been 
developed but are not applicable to young athletes. For example, 
the ESC HCM Risk- SCD Score estimates the 5- year risk of SCD 
in patients with HCM but specifically states it should not be used 
in elite/competitive athletes or paediatric patients<16 years.
While the precise risk of SCD in a young athlete with HCM is 
challenging to predict, an estimate of risk can be drawn from our 
current understanding of disease prevalence and the incidence of 
SCD in competitive athletes (table 1). Based on the annual inci-
dence of SCD in prior studies, the proportion of HCM- related 
SCD and a disease prevalence from 1:2000 to 1:500 in athletes, 
we estimate the annual risk of SCD in young athletes with HCM 
is between 0.1% and 6.6% per year depending on the athlete 
population.1 2 39 While the risk may exceed the upper limit of 
what was calculated, the estimated range is consistent with 
annual mortality rates previously reported in younger patients 
with HCM.28 30 However, the spectrum of disease phenotypes 
in athletes is likely less severe than that in the general popu-
lation, as athletes competing at a high level may not exhibit 
high- risk phenotypes that could potentially impede athletic 
performance (ie, greater maximum wall thickness or high left 
ventricular outflow tract gradients). Phenotypic features of 
the athletic HCM heart were reported in 106 young athletes 
(14–35 years) with HCM and compared with 101 sedentary 
patients with HCM.40 Athletes with HCM had milder LVH 
(15.8±3.4 mm vs 19.7±6.5 mm, p<0.001) that was frequently 
confined to the apex (36%), larger left ventricular cavity dimen-
sions (47.8±6.0 mm vs 44.3±7.7 mm, p<0.001) and superior 
indices of diastolic function (average E/E′ 7.9±2.4 vs 10.7±3.9, 
p<0.001) compared with sedentary patients with HCM.40
Our estimates are influenced by the reported incidence of 
SCD in the athlete population, and higher mortality rates were 
calculated in black athletes, male athletes and athletes in higher 
risk sports such as basketball and soccer. Importantly, estimates 
do not account for resuscitated cardiac arrest in which survival 
has been reported in up to 48% of athlete cases.41 Thus, the 
annual risk of any life- threatening ventricular arrhythmia will be 
higher than the estimates presented.
IS EXERCISE BENEFICIAL IN PATIENTS WITH HCM?
Recent studies have demonstrated that exercise is beneficial 
for older patients with HCM. The Randomized Exploratory 
Study of Exercise Training in Hypertrophic Cardiomyopathy 
trial established that 16 weeks of moderate- intensity exercise 
resulted in a small but significant increase in exercise capacity in 
older adult patients (mean age 50.4 years) with HCM.42 These 
modest increases in cardiorespiratory fitness may be associated 
with reductions in cardiovascular mortality.43 Likewise, a retro-
spective survey of adult patients with HCM (mean age 49 years) 
suggested that lifetime vigorous exercise correlated with favour-
able diastolic function and was not associated with ventricular 
arrhythmias.44 A supervised cardiac rehabilitation exercise 
programme in symptomatic patients with HCM (mean age 
62±13 years) also demonstrated improved functional capacity.45 
While these studies inform activity recommendations for older 
adult patients with HCM, they were not designed to establish 
safety in adolescent and young adult competitive athletes where 
the disease course and exercise intensity may be profoundly 
different.
EVENTS DURING REST, SLEEP OR EXERCISE?
While the occurrence of SCA/SCD during exercise is well docu-
mented in patients with HCM, there is debate if exercise itself 
presents a higher risk than more sedentary activity. This contro-
versy was recently fueled by a 2019 study examining HCM- 
related SCD in the general (non- athlete) population (median 
age 35 years) in Ontario, Canada, that reported 71% of cases 
occurred during sleep, rest or light activity.46 Similarly, in a study 
of 196 decedents with HCM (age 43±18 years) reviewed by a 
specialist cardiac pathology centre in the UK, SCD during exer-
cise occurred in just 46 (23%) individuals but was confined to 
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younger male subjects (age 30±11 years).47 Comorbid obstruc-
tive sleep apnea which may be more common in older patients 
with HCM has been proposed as a risk factor for SCD during 
sleep, although evidence is limited.48 In younger athletes who 
engage in intensive training more regularly, SCD during exer-
cise appears to be more common. In a study of 1306 cases of 
SCD in young athletes including 302 from HCM, 74% of events 
occurred during practice or competition.3 In a cohort of 79 cases 
of SCD in college athletes (8% from HCM), 56% occurred with 
exertion, 22% at rest and 14% during sleep (9% unknown).1 In 
a prospective series of 179 cases of SCA/SCD in US competitive 
athletes, 76.0% occurred during or within 1 hour of exercise and 
21.8% during rest or sleep (2.2% unknown).2 Additional reports 
from Sweden and Spain also found cardiomyopathy to be the 
most common cause of exercise- related SCD in athletes.49 50
Histopathologically, HCM presents an unpredictable arrhyth-
mogenic substrate demonstrating myocardial disarray and 
interstitial and myocardial scarring as a result of microvascular 
ischaemia.29 Athletes engaging in intense exercise undergo 
powerful epinephrine surges, extreme metabolic stresses and 
dehydration, all of which could provoke a ventricular tachyar-
rhythmia in the setting of a pathological myocardial substrate. 
The effect of physiological cardiac adaptations potentially 
augmenting pathological hypertrophy in athletes with HCM 
raises additional concern. In a 2019 study of American foot-
ball players, weight gain and increased systolic blood pressure 
were associated with development of a pathological cardiovas-
cular phenotype consisting of concentric LVH, arterial stiffening 
and reduced left ventricular diastolic function.51 The potential 
adverse consequences of maladaptive cardiac remodelling in 
athletes with a genetic cardiomyopathy are unknown but poten-
tially troubling. Could exercise- induced substrate changes in 
patients with HCM make sudden death at any time (during rest 
or physical exertion) more likely?
The proportion of athletes with SCA/SCD during exercise is 
further magnified considering vigorous exercise only accounts 
for one- sixth or less of the total hours in the day even in the most 
dedicated athletes. Thus, while SCA/SCD can occur at any time 
in patients with HCM, evidence suggests that intense exercise is 
a risk factor for potentially lethal ventricular tachyarrhythmias, 
especially in younger male individuals.
DOES DISQUALIFICATION IN ATHLETES WITH HCM 
DECREASE SCD?
While limited evidence is available, two prospective studies in young 
competitive athletes provide important insights into whether stop-
ping competitive sports reduces mortality in athletes diagnosed with 
Table 1 Estimated annual mortality rate from sudden cardiac death in young athletes with HCM
Modellingassumptions:
 ► Prevalence of HCM in the athlete population ranges from 1:2000 to 1:500 persons.
 ► Supposing 500 000 athletes, the total number of athletes with HCM is 250–1000 persons.
 ► Annual incidence rates cited include only SCD and do not include resuscitated cardiac arrest; thus actual rates of all life- threatening ventricular arrhythmias will be higher.
 ► Proportion of SCD from HCM listed is based on autopsy confirmation or in vivo diagnosis.
Study and athlete 
population
Annual incidence of SCD (athlete- 
years)
Total Number of SCD 
Cases (in a population of
500000)
Proportion of SCD 
from HCM
Number of Cases of 
SCD from HCM
Annual mortality rate 
from HCM- related SCD
Maron et al19
  College athletes 1:62 500 8 32.80% 2.6 0.26%–1.0%
  Black college athletes 1:26 315 19 44.70% 8.5 0.85%–3.4%
  White college athletes 1:142 857 3.5 44.70% 1.6 0.2%–0.6%
Harmon et al1
  College athletes 1:53 703 9.3 8% 0.7 0.07%–0.3%
  Black college athletes 1:21 491 23.3 8% 1.9 0.2%–0.8%
  White college athletes 1:68 354 7.3 8% 0.6 0.06%–0.2%
  Division I male 
basketball
1:5200 96.2 8% 7.7 0.8%–3%
Maron et al3 From the US national registry
  Black/minority athletes 1:12 778 39.1 42% 16.4 1.6%–6.6%
  White athletes 1:60 746 8.2 31% 2.6 0.3%–1.0%
Harmon et al22
  Male high school 
athletes
1:68 742 7.3 14% 1 0.1%–0.4%
  Female high school 
athletes
1:316 679 1.6 14% 0.2 0.02%–0.08%
Malhotra et al20
  Elite adolescent soccer 
(95% male)*
1:14 794 33.8 37.50% 12.7 1.3%–5.1%
Corrado et al52
  Competitive 
athletes≤35 years old 
from Veneto region of 
Italy†
1:62 500 8 2% 0.2 0.02%–0.08%
*Study population underwent cardiovascular screening with ECG and echocardiogram at age 16 years.
†Study population underwent annual cardiovascular screening with ECG.
HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death.
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HCM. A 1998 study reported on 33 335 screened athletes (mean 
age 19 years) from the Veneto region of Italy.52 HCM was identi-
fied in 22 athletes, all of whom were disqualified from competitive 
sport and survived over 8 years of follow- up. One athlete with unde-
tected HCM died, compared with 16 HCM- related deaths in the 
unscreened (non- athlete) general population. While the study was 
not powered to provide definitive conclusions, early detection of 
HCM in competitive athletes followed by sports disqualification led 
to a 73% risk reduction in mortality.52 Similarly, 11 168 elite adoles-
cent soccer players (mean age 16.4 years) from the UK underwent 
cardiovascular screening and were followed for a mean of 10.6 
years.20 Five athletes were diagnosed with HCM through screening; 
three athletes stopped competitive soccer and survived, while two 
athletes continued playing against medical advice and died during 
exercise.20
POTENTIAL HARMS OF DISQUALIFICATION
The disqualification of a young athlete from competitive sports is a 
complex and difficult decision that requires serious considerations. 
Not surprisingly, athletes diagnosed with potentially lethal cardiac 
disorders are at risk for significant psychological distress.53 Sports 
participation establishes healthy lifestyles, builds self- confidence 
and provides an avenue to educational scholarships or the poten-
tial financial rewards of professional sport that may carry different 
significance depending on the athlete’s socioeconomic background. 
Athletic dedication and success also are integral to the self- identify 
of a young athlete, and removal from competitive sports likely will 
have short- term and possibly long- term consequences on mental and 
emotional health. In addition, risk tolerance or avoidance is an indi-
vidual assessment and important for patient autonomy in healthcare 
decisions.
A 2014 study examined the psychological impact of being diag-
nosed with a serious or potentially lethal cardiac disease in 25 
young competitive athletes, including 3 athletes with HCM that 
were ultimately disqualified.54 Athletes progressed through four 
psychological stages following sports disqualification including: (1) 
immediate challenges to athlete identity, (2) grief/coping, (3) adap-
tation and (4) acceptance.54 Risk factors for increased psycholog-
ical morbidity included a higher level of competition, permanent 
disqualification from sports, persistent reminders of their disease (eg, 
daily medication, monitoring heart rate during activity) and unan-
ticipated outcomes (eg, failed procedures). Additionally, disqualified 
athletes were at risk for losing the structure and support afforded 
by a team environment, and elite or professional athletes may have 
difficulty shifting to an alternative career. However, early diagnosis 
also led to new goals such as mentoring or coaching. Remarkably, all 
athletes diagnosed through advanced cardiovascular screening stated 
they would repeat the process, suggesting SCD risk reduction was 
accepted over sports particpation.54
Thus, the potential harms of sports disqualification—loss of 
self- identity, loss of educational scholarship, loss of potential 
income and the risk of depression or mental health issues—should 
be carefully weighed and addressed in the shared decision- making 
process. Regardless of the outcome, mechanisms to provide 
emotional and psychological support for athletes diagnosed with 
a potentially career altering heart condition should be in place. 
In addition, while difficult to replace the social and psychological 
benefits of competitive sports, a programme that maintains safe 
levels of physical activity and cardiorespiratory fitness should be 
advised for athletes no longer participating in competitive sports. 
Studies defining the specifics of such programmes are still in the 
developmental stages.
LIMITATIONS OF SHARED DECISION-MAKING
Other issues warrant consideration in the context of life- critical 
shared decision- making. Most young athletes do not consider them-
selves vulnerable to the risks of sport, catastrophic injury or sudden 
death. In combination with the lure of fame and/or fortune or family 
pressure for economic gain, this raises an important ethical question: 
can young athletes truly make an unbiased and informed decision 
under duress?
Educational institutions, clubs and sports organisations also 
are impacted by the decision. High school and college admin-
istrations have a responsibility to protect the health and safety 
of their student athletes and potential liability concerns may 
shape a more conservative risk tolerance. In professional sports, 
some clubs may be adverse to even the small prospect of a player 
suffering SCA/SCD during a widely publicised event.
Medical team members, including team physicians and 
cardiologists, also may view eligibility decisions from different 
perspectives. Team physicians commonly provide medical ‘clear-
ance’ to play sports. A determination of safety and eligibility is 
required for every athlete at the time of their preparticipation 
evaluation. Outside of cardiovascular concerns, team physi-
cians periodically place activity restrictions or even perma-
nent eligibility restrictions in other areas relevant to the health 
and safety of athletes—such as repetitive concussions, cervical 
spinal stenosis, or worsening joint degeneration—in which the 
competitive career of an athlete is stopped prematurely. While 
the best interest of the athlete is always the top priority, sports 
medicine professionals also may have an obligation to their club 
and an ethical responsibility to society to ensure safe athletic 
participation.
Consequently, in the setting of different perspectives or perhaps 
even ‘competing interests’, how does the shared decision- making 
process move forward?
WHO ULTIMATELY DECIDES?
Ideally, an informed athlete will come to the same conclusion 
about sports participation as their medical team. However, the 
athlete, team physician, cardiologist, athletic trainer and school or 
club may have different thresholds to permit a return to compet-
itive sports. For instance, what happens when the cardiologist 
recognises an athlete with HCM has an elevated risk of SCD 
but supports the athlete’s right to choose to play and the team 
physician recommends against it? Or if the team cardiologist/
consultant recommends against participation but the athlete’s 
cardiologist or second opinion endorses a return to play? If all 
parties do not agree, shared decision- making ultimately comes 
down to who has the final authority to give the ‘yes’ or ‘no’ 
regarding eligibility. Allowing the athlete to make the final 
decision may unintentionally remove everyone else from the 
shared- decision- making process. Undoubtedly, balancing patient 
autonomy with respect for the common good in order to prevent 
catastrophic events in sport is a massive challenge. A proposed 
framework to consider competitive sports restriction in athletes 
based on the risk of HCM- related SCD is provided in figure 1.
In the USA, legal precedent supports that high school students 
with heart disease have no compelling right to participate in 
interscholastic sports without medical clearance and that college 
athletes with life- threatening cardiac conditions can be medically 
disqualified and eligibility decisions reside with the team physi-
cian.55 56 Some professional sports leagues, such as the National 
Football League (NFL), also explicitly state in the collective 
bargaining agreement with the NFL Players Association that the 
head team physician for each club has final decision authority. In 
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some instances, one team may judge an athlete at unacceptable 
risk, while another, presented with the same evidence, may allow 
the athlete to participate. In Italy, guidelines for sports eligibility 
in athletes with heart disease is actually written into law.57 Thus, 
eligibility decisions may be influenced by the policies and laws 
dictated by the relevant country or sports governing body.
CONCLUSION
The diagnosis of serious cardiovascular disease in a competi-
tive athlete presents complex issues regarding safety, patient 
autonomy and medical decision- making engrossed by scientific 
and clinical uncertainty. For disorders where effective risk reduc-
tion is supported by evidence, continued sports participation in 
treatment- compliant patients seems reasonable. HCM comprises 
an electrophysiological substrate that is unpredictable and poten-
tially vulnerable to the stresses of intense exercise even in the 
absence of conventional risk markers. Epidemiological evidence 
indicates that HCM is an important cause of SCD in young 
athletes and sports restriction may prevent SCD. However, the 
quality of evidence is not sufficient to precisely define risk across 
all athletes diagnosed with HCM, making eligibility decisions 
very challenging in the era of shared decision- making. In addi-
tion, we lack adequately powered studies that investigate safety 
with exercise and HCM, particularly in young athletes partici-
pating in competitive sport who appear to be at greater risk. While 
moderate- intensity exercise seems beneficial in older patients 
with HCM, high- intensity training in young athletes with HCM 
may trigger life- threatening ventricular tachyarrhythmias. We 
estimate an annual risk of 0.1%–6.6% for the occurrence of SCD 
in adolescent or young adult competitive athletes with HCM. 
Higher risk is exhibited in males and athletes participating in 
basketball, soccer and American football. Risk stratification tools 
have been developed for the clinical management of patients 
with HCM. These were not derived from athletic populations 
What is already known
 ► Sudden cardiac death (SCD) is the leading cause of non- 
traumatic fatalities in young competitive athletes (<30 years 
old) during sports and exercise.
 ► Evidence supports that hypertrophic cardiomyopathy (HCM) 
is consistently represented in SCD series in young athletes, 
deeming it an important cause of SCD in young athletes.
 ► Guidelines for sports participation in athletes with SCD- 
associated cardiovascular conditions have evolved where the 
treatment options, potential harms and benefits of continued 
sports participation and patient values are discussed within a 
shared decision- making model.
Figure 1 Proposed framework for eligibility decisions in athletes with HCM. HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter 
defibrillator; LGE, late gadolinium enhancement; LVOT left ventricular outflow tract. *Strongly consider competitive sport restriction in individuals 
with multiple risk factors. †ICDs lower the risk of HCM- related SCD, but recommendations for an ICD are based on conventional high- risk markers and 
an ICD should not be placed for the sole purpose of allowing sports participation. ˆConventional risk markers include: family history of HCM- related 
sudden death, unexplained syncope, multiple or repetitive episodes of non- sustained ventricular tachycardia, massive left ventricular hypertrophy 
(wall thickness ≥30 mm), left ventricular apical aneurysm or an ejection fraction <50%.
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and do not consider some of the unique considerations raised 
in this review. However, until a suitable alternative is avail-
able, these prognostic tools can be used with caution. Shared 
decision- making implies that the anticipated risk is acceptable 
to the patient, family, medical team and club/school. Based on 
this critical analysis, competitive sports participation in young 
athletes with HCM should be approached with caution, appro-
priate counselling and careful consideration for sports restriction 
based on HCM- related SCD risk. Additional research is needed 
to determine safe levels of exercise and sports participation in 
young persons with HCM and to develop evidence- based SCD 
risk stratification algorithms in athletes.
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